Journal of Clinical Oncology · 2003 · 120 citations · 21 references
MedicineOncologyUrologyChemotherapyGenitourinary OncologyUrologic OncologyBladder CancerBladder Function AssessmentMetastatic Cancer ManagementMetastatic Urologic CancerPalliative ChemotherapySupportive Care In CancerCancer-related Quality Of LifeDistant Metastasis StagingMetastatic Bladder CancerPrognostic Factors AnalysisPrognostic ModelsQuality Of Life PrognosisTumor-node-metastasis StagingVisceral Metastases
PURPOSE: This retrospective analysis examined prognostic significance of health-related quality-of-life (HRQoL) parameters combined with baseline clinical factors on outcomes (overall survival, time to progressive disease, and time to treatment failure) in bladder cancer. PATIENTS AND METHODS: Outcome and HRQoL (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30) data were collected prospectively in a phase III study assessing gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in locally advanced or metastatic bladder cancer. Prespecified baseline clinical factors (performance status, tumor-node-metastasis staging, visceral metastases [VM], alkaline phosphatase [AP] level, number of metastatic sites, prior radiotherapy, disease measurability, sex, time from diagnosis, and sites of disease) and selected HRQoL parameters (global QoL; all functional scales; symptoms: pain, fatigue, insomnia, dyspnea, anorexia) were evaluated using Cox's proportional hazards model. Factors with individual prognostic value (P <.05) on outcomes in univariate models were assessed for joint prognostic value in a multivariate model. A final model was developed using a backward selection strategy. RESULTS: Patients with baseline HRQoL were included (364 of 405, 90%). The final model predicted longer survival with low/normal AP levels, no VM, high physical functioning, low role functioning, and no anorexia. Positive prognostic factors for time to progressive disease were good performance status, low/normal AP levels, no VM, and minimal fatigue; for time to treatment failure, they were low/normal AP levels, minimal fatigue, and no anorexia. Global QoL was a significant predictor of outcome in univariate analyses but was not retained in the multivariate model. CONCLUSION: HRQoL parameters are independent prognostic factors for outcome in advanced bladder cancer; their prognostic importance needs further evaluation.
21
N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations
Hans von der Maase, Steen Werner Hansen, J.T. Roberts et al. · Journal of Clinical Oncology · 2000 · 2.3K citations · Full text
Medicine, Oncology, Pharmacology +11
Who should measure quality of life, the doctor or the patient?
ML Slevin, Hilary Plant, Denis J. Lynch et al. · British Journal of Cancer · 1988 · 913 citations · Full text